---
title: "Jacobio Pharmaceuticals Group: Revenue up 1499% and net profit reached RMB600.6 million, fueled by major licensing deals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296791061.md"
description: "Revenue surged 1499% year-over-year to RMB730.9 million, driven by major licensing deals and clinical progress, resulting in a net profit of RMB600.6 million. The company advanced its oncology pipeline, secured a US$100 million upfront from AstraZeneca, and maintained strong liquidity.Original document: Jacobio Pharmaceuticals Group Co., Ltd. [1167] Earnings Release — Aug. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-24T12:48:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296791061.md)
  - [en](https://longbridge.com/en/news/296791061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296791061.md)
generator: "portal-rs"
---

# Jacobio Pharmaceuticals Group: Revenue up 1499% and net profit reached RMB600.6 million, fueled by major licensing deals

Revenue surged 1499% year-over-year to RMB730.9 million, driven by major licensing deals and clinical progress, resulting in a net profit of RMB600.6 million. The company advanced its oncology pipeline, secured a US$100 million upfront from AstraZeneca, and maintained strong liquidity.

Original document: Jacobio Pharmaceuticals Group Co., Ltd. \[1167\] Earnings Release — Aug. 24 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [01167.HK](https://longbridge.com/en/quote/01167.HK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [Is Samsung’s $72B payout a vote of confidence in AI?](https://longbridge.com/en/news/296469504.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**